These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25101488)

  • 1. Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.
    Santella JB; Gardner DS; Duncia JV; Wu H; Dhar M; Cavallaro C; Tebben AJ; Carter PH; Barrish JC; Yarde M; Briceno SW; Cvijic ME; Grafstrom RR; Liu R; Patel SR; Watson AJ; Yang G; Rose AV; Vickery RD; Caceres-Cortes J; Caporuscio C; Camac DM; Khan JA; An Y; Foster WR; Davies P; Hynes J
    J Med Chem; 2014 Sep; 57(18):7550-64. PubMed ID: 25101488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of BMS-457, a potent and selective CCR1 antagonist.
    Gardner DS; Santella JB; Duncia JV; Carter PH; Dhar TG; Wu H; Guo W; Cavallaro C; Van Kirk K; Yarde M; Briceno SW; Grafstrom RR; Liu R; Patel SR; Tebben AJ; Camac D; Khan J; Watson A; Yang G; Rose A; Foster WR; Cvijic ME; Davies P; Hynes J
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3833-40. PubMed ID: 23707259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR.
    Khan JA; Camac DM; Low S; Tebben AJ; Wensel DL; Wright MC; Su J; Jenny V; Gupta RD; Ruzanov M; Russo KA; Bell A; An Y; Bryson JW; Gao M; Gambhire P; Baldwin ET; Gardner D; Cavallaro CL; Duncia JV; Hynes J
    J Mol Biol; 2015 Feb; 427(4):924-942. PubMed ID: 25579995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.
    Merritt JR; Liu J; Quadros E; Morris ML; Liu R; Zhang R; Jacob B; Postelnek J; Hicks CM; Chen W; Kimble EF; Rogers WL; O'Brien L; White N; Desai H; Bansal S; King G; Ohlmeyer MJ; Appell KC; Webb ML
    J Med Chem; 2009 Mar; 52(5):1295-301. PubMed ID: 19183043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD-4818, a chemokine CCR1 antagonist: WO2008103126 and WO2009011653.
    Norman P
    Expert Opin Ther Pat; 2009 Nov; 19(11):1629-33. PubMed ID: 19586423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spirocyclic compounds, potent CCR1 antagonists.
    Hossain N; Ivanova S; Bergare J; Eriksson T
    Bioorg Med Chem Lett; 2013 Mar; 23(6):1883-6. PubMed ID: 23414842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring a model of a chemokine receptor/ligand complex in an explicit membrane environment by molecular dynamics simulation: the human CCR1 receptor.
    Shahlaei M; Madadkar-Sobhani A; Fassihi A; Saghaie L
    J Chem Inf Model; 2011 Oct; 51(10):2717-30. PubMed ID: 21910472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-pharmacophere models for CC chemokine receptor 1 antagonists.
    Liu Y; Andre P; Wei J; Zhao K
    Med Chem; 2009 Jul; 5(4):318-24. PubMed ID: 19689388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.
    Carter PH; Hynes J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1609-18. PubMed ID: 20858032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
    Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure activity relationships of fused bicyclic and urea derivatives of spirocyclic compounds as potent CCR1 antagonists.
    Hossain N; Mensonides-Harsema M; Cooper ME; Eriksson T; Ivanova S; Bergström L
    Bioorg Med Chem Lett; 2014 Jan; 24(1):108-12. PubMed ID: 24332486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
    Vergunst CE; Gerlag DM; von Moltke L; Karol M; Wyant T; Chi X; Matzkin E; Leach T; Tak PP
    Arthritis Rheum; 2009 Dec; 60(12):3572-81. PubMed ID: 19950299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent, selective, and orally bioavailable acidic 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor: discovery of 2-[(3S)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl]-3-piperidyl]acetic acid (AZD4017).
    Scott JS; Bowker SS; Deschoolmeester J; Gerhardt S; Hargreaves D; Kilgour E; Lloyd A; Mayers RM; McCoull W; Newcombe NJ; Ogg D; Packer MJ; Rees A; Revill J; Schofield P; Selmi N; Swales JG; Whittamore PR
    J Med Chem; 2012 Jun; 55(12):5951-64. PubMed ID: 22691057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCR1 antagonists: what have we learned from clinical trials.
    Gladue RP; Brown MF; Zwillich SH
    Curr Top Med Chem; 2010; 10(13):1268-77. PubMed ID: 20536425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
    Santella JB; Gardner DS; Yao W; Shi C; Reddy P; Tebben AJ; DeLucca GV; Wacker DA; Watson PS; Welch PK; Wadman EA; Davies P; Solomon KA; Graden DM; Yeleswaram S; Mandlekar S; Kariv I; Decicco CP; Ko SS; Carter PH; Duncia JV
    Bioorg Med Chem Lett; 2008 Jan; 18(2):576-85. PubMed ID: 18096386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
    Furber M; Alcaraz L; Luckhurst C; Bahl A; Beaton H; Bowers K; Collington J; Denton R; Donald D; Kinchin E; MacDonald C; Rigby A; Riley R; Soars M; Springthorpe B; Webborn P
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7702-6. PubMed ID: 23142617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel series of human CCR1 antagonists.
    Xie YF; Sircar I; Lake K; Komandla M; Ligsay K; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Sakurai N; Barbosa M; Jack R
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2215-21. PubMed ID: 18329267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of pyrazole amides as antagonists of CCR1.
    Harcken C; Sarko C; Mao C; Lord J; Raudenbush B; Razavi H; Liu P; Swinamer A; Disalvo D; Lee T; Lin S; Kukulka A; Grbic H; Patel M; Patel M; Fletcher K; Joseph D; White D; Amodeo L; Berg K; Brown M; Thomson DS
    Bioorg Med Chem Lett; 2019 Feb; 29(3):435-440. PubMed ID: 30455146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of CCR1 antagonists for multiple myeloma.
    Karash AR; Gilchrist A
    Future Med Chem; 2011 Nov; 3(15):1889-908. PubMed ID: 22023033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure activity relationships of spirocyclic compounds as potent CCR1 antagonists.
    Hossain N; Ivanova S; Bergare J; Mensonides-Harsema M; Cooper ME
    Bioorg Med Chem Lett; 2013 Jun; 23(12):3500-4. PubMed ID: 23659855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.